Pallavi Alegete
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pallavi Alegete has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Shadab Anwar Hashmi
CSIR - Indian Institute of Chemical Technology 1
2 shared publicationsJagadeshwar Reddy Thota
CSIR - Indian Institute of Chemical Technology 1
1 shared publicationKrishna Rao Vankalapati
Department of Chemistry JNTUH College of Engineering Jagtial Telangana State India
1 shared publicationMeghana Ajmeera
Department of Analytical and Structural Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad 500007, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
1 shared publicationNavya Sahithi Pelimelli
CSIR - Indian Institute of Chemical Technology 1
1 shared publicationSaisudha Byreddy
Academy of scientific and Innovative research (AcSIR) Ghaziabad India
1 shared publication
Latest Publications
- 14 June 2026
- Published by Elsevier in Journal of Chromatography B
- Vol. 1281, 125182
Stability-indicating RP-HPLC–DAD method for aspirin and vonoprazan using analytical quality by design and comprehensive greenness assessment
- 14 June 2026
- Published by Elsevier in Journal of Chromatography B
- Vol. 1281, 125182
Stability-indicating RP-HPLC–DAD method for aspirin and vonoprazan using analytical quality by design and comprehensive greenness assessment
- Open Access
- 7 January 2026
- Published by The Royal Society in Royal Society Open Science
- Vol. 13 (1)
A QbD-guided, eco-friendly UHPLC method for simultaneous estimation of tezacaftor and ivacaftor: a stability-indicating and green analytical approach
This study reports the development and validation of a novel ultra-high-performance liquid chromatography (UHPLC) method that is both stability indicating and environmentally sustainable, intended for the simultaneous quantification of tezacaftor (TZF) and ivacaftor (IVF) in pharmaceutical formulations. Using analytical quality-by-design (AQbD) principles, critical method parameters (CMPs), including flow rate and column temperature, were optimized using central composite design (CCD). Separation was achieved on an ACE Excel Super C18 column (100 × 2.1 mm, 2 µm) using an isocratic mobile phase of acetonitrile and water at 75 : 25 v/v, 0.3 ml min−1 , with detection at 254 nm. Validation according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q2(R1) demonstrated excellent linearity (R² > 0.999), accuracy (98–102% recovery), precision (% relative standard deviation (% r.s.d.) < 2%) and sensitivity with limits of detection (LOD) and quantification (LOQ) 0.5/1.5 µg ml−1 (TZF) and 0.3/1.0 µg ml−1 (IVF). The stability-indicating nature of the method was confirmed through forced-degradation studies under various stress conditions, with peak purity analysis supporting its specificity. Sustainability assessment using the Analytical Eco-Scale (score: 80), GAPI and AGREE tools verified the method’s eco-friendly profile.
- 7 January 2026
- Published by The Royal Society in Royal Society Open Science
- Vol. 13 (1)
Open AccessA QbD-guided, eco-friendly UHPLC method for simultaneous estimation of tezacaftor and ivacaftor: a stability-indicating and green analytical approach
This study reports the development and validation of a novel ultra-high-performance liquid chromatography (UHPLC) method that is both stability indicating and environmentally sustainable, intended for the simultaneous quantification of tezacaftor (TZF) and ivacaftor (IVF) in pharmaceutical formulations. Using analytical quality-by-design (AQbD) principles, critical method parameters (CMPs), including flow rate and column temperature, were optimized using central composite design (CCD). Separation was achieved on an ACE Excel Super C18 column (100 × 2.1 mm, 2 µm) using an isocratic mobile phase of acetonitrile and water at 75 : 25 v/v, 0.3 ml min−1 , with detection at 254 nm. Validation according to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q2(R1) demonstrated excellent linearity (R² > 0.999), accuracy (98–102% recovery), precision (% relative standard deviation (% r.s.d.) < 2%) and sensitivity with limits of detection (LOD) and quantification (LOQ) 0.5/1.5 µg ml−1 (TZF) and 0.3/1.0 µg ml−1 (IVF). The stability-indicating nature of the method was confirmed through forced-degradation studies under various stress conditions, with peak purity analysis supporting its specificity. Sustainability assessment using the Analytical Eco-Scale (score: 80), GAPI and AGREE tools verified the method’s eco-friendly profile.
- Open Access
- 28 June 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-19
QbD green analytical procedure for the quantification of tolvaptan by utilizing stability indicating UHPLC method
For the first time a new QbD-assisted green stability indicating ultra-high-performance liquid chromatography (UHPLC) method was developed and validated for quantifying Tolvaptan. The method is simple, quick, cost-effective, and stable, and it was used to formulate a quality target product profile (QTPP) with strategically defined critical analytical attributes (CAAs) to meet specific criteria. Chromatographic separation was undertaken using a 10 cm long column of ACE excel super C18 with an interior diameter of 2.1 mm and particle size of 1.7 µm. The analysis was performed under controlled conditions at 25 ℃ with the mobile phase flowing at a rate of 0.2 mL/min and detection occurring at 220 nm. Injected 3 µL of standard by using an isocratic mobile phase system consisting of acetonitrile and water in a 95:5 v/v ratio. The diluents, prepared by mixing acetonitrile with water at a 90:10 volumetric ratio, were utilized. The analyte’s retention time was determined to be 1.63 min. The developed method provided reliable results with accuracy exceeding 99% and a correlation coefficient exceeding 0.999 ranged between 10 and 150 µg/mL across the range for LOQ—150% levels. Notably, during forced degradation testing, Tolvaptan exhibited susceptibility to acidic hydrolysis. The method effectively separated degradation products during stress testing, demonstrating its stability-indicating status. Environmental sustainability assessment of the developed method was conducted through the investigation of various indicators of Complex GAPI, Analytical Eco scale and Analytical GREEness and it was concluded the optimized method aligns with environmentally friendly practices.
- 28 June 2024
- Published by Springer Nature in BMC Chemistry
- Vol. 18 (1) , 1-19
Open AccessQbD green analytical procedure for the quantification of tolvaptan by utilizing stability indicating UHPLC method
For the first time a new QbD-assisted green stability indicating ultra-high-performance liquid chromatography (UHPLC) method was developed and validated for quantifying Tolvaptan. The method is simple, quick, cost-effective, and stable, and it was used to formulate a quality target product profile (QTPP) with strategically defined critical analytical attributes (CAAs) to meet specific criteria. Chromatographic separation was undertaken using a 10 cm long column of ACE excel super C18 with an interior diameter of 2.1 mm and particle size of 1.7 µm. The analysis was performed under controlled conditions at 25 ℃ with the mobile phase flowing at a rate of 0.2 mL/min and detection occurring at 220 nm. Injected 3 µL of standard by using an isocratic mobile phase system consisting of acetonitrile and water in a 95:5 v/v ratio. The diluents, prepared by mixing acetonitrile with water at a 90:10 volumetric ratio, were utilized. The analyte’s retention time was determined to be 1.63 min. The developed method provided reliable results with accuracy exceeding 99% and a correlation coefficient exceeding 0.999 ranged between 10 and 150 µg/mL across the range for LOQ—150% levels. Notably, during forced degradation testing, Tolvaptan exhibited susceptibility to acidic hydrolysis. The method effectively separated degradation products during stress testing, demonstrating its stability-indicating status. Environmental sustainability assessment of the developed method was conducted through the investigation of various indicators of Complex GAPI, Analytical Eco scale and Analytical GREEness and it was concluded the optimized method aligns with environmentally friendly practices.
- 16 January 2024
- Published by Wiley in Biomedical Chromatography
- Vol. 38 (3) , e5812
Development of a novel quality by design–enabled stability‐indicating HPLC method and its validation for the quantification of nirmatrelvir in bulk and pharmaceutical dosage forms
A systematic and novel quality by design–enabled, rapid, simple, and economic stability–indicating HPLC method for quantifying nirmatrelvir (NMT) was successfully developed and validated. An analytical target profile (ATP) was established, and critical analytical attributes (CAAs) were allocated to meet the ATP requirements. The method used chromatographic separation using a Purosphere column with a 4.6 mm inner diameter × 250 mm (2.5 μm). The analysis occurred at 50°C with a flow rate of 1.2 mL/min and detection at 220 nm. A 10 μL sample was injected, and the mobile phase consisted of two components: mobile phase A, containing 0.1% formic acid in water (20%), and mobile phase B, containing 0.1% formic acid in acetonitrile (80%). The diluent was prepared by mixing acetonitrile and water at a 90:10 v/v ratio. The retention time for the analyte was determined to be 2.78 min. Accuracy exceeded 99%, and the correlation coefficient was greater than 0.999. The validated HPLC method was characterized as precise, accurate, and robust. Significantly, NMT was found to be susceptible to alkaline, acidic, and peroxide conditions during forced degradation testing. The stability‐indicating method developed effectively separated the degradation products formed during stress testing, underlining its effectiveness in stability testing and offering accuracy, reliability, and sensitivity in determining NMT.
- 16 January 2024
- Published by Wiley in Biomedical Chromatography
- Vol. 38 (3) , e5812
Development of a novel quality by design–enabled stability‐indicating HPLC method and its validation for the quantification of nirmatrelvir in bulk and pharmaceutical dosage forms
A systematic and novel quality by design–enabled, rapid, simple, and economic stability–indicating HPLC method for quantifying nirmatrelvir (NMT) was successfully developed and validated. An analytical target profile (ATP) was established, and critical analytical attributes (CAAs) were allocated to meet the ATP requirements. The method used chromatographic separation using a Purosphere column with a 4.6 mm inner diameter × 250 mm (2.5 μm). The analysis occurred at 50°C with a flow rate of 1.2 mL/min and detection at 220 nm. A 10 μL sample was injected, and the mobile phase consisted of two components: mobile phase A, containing 0.1% formic acid in water (20%), and mobile phase B, containing 0.1% formic acid in acetonitrile (80%). The diluent was prepared by mixing acetonitrile and water at a 90:10 v/v ratio. The retention time for the analyte was determined to be 2.78 min. Accuracy exceeded 99%, and the correlation coefficient was greater than 0.999. The validated HPLC method was characterized as precise, accurate, and robust. Significantly, NMT was found to be susceptible to alkaline, acidic, and peroxide conditions during forced degradation testing. The stability‐indicating method developed effectively separated the degradation products formed during stress testing, underlining its effectiveness in stability testing and offering accuracy, reliability, and sensitivity in determining NMT.
- 4 November 2020
- Published by Wiley in Biomedical Chromatography
- Vol. 35 (4) , e5019
Stability‐indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of metformin, linagliptin, and empagliflozin in bulk and pharmaceutical dosage form
A rapid stability‐indicating reversed phase‐ultrapure liquid chromatography (RP‐UPLC) was developed and validated for the estimation of metformin (MET), linagliptin (LIN), and empagliflozin (EMP) combination in bulk and tablet dosage form using Kromasil C18 column (2.1 × 50 mm, 1.8 μm) as a stationary phase and a mixture solution of 40% phosphate buffer (pH = 3) and 60% acetonitrile as mobile phase at a flow rate of 0.6 mL/min. The detection was performed at 248 nm using a photodiode array detector. The linearity, sensitivity, selectivity, robustness, specificity, precision, and accuracy were determined. The peak area response–concentration curve was rectilinear over the range of 50–150 (MET), 5–15 (LIN), and 10–30 μg/mL (EMP) with quantitation limits of 0.042 (MET), 0.023 (LIN), and 0.059 μg/mL (EMP). The proposed method was successfully validated for the determination of MET, LIN, and EMP simultaneously in combined tablet dosage form. The performance of the proposed method was compared with reported RP‐UPLC methods and found to be rapid and economical. The developed and validated stability‐indicating RP‐UPLC method was appropriate for the quality control and drug analysis.
- 4 November 2020
- Published by Wiley in Biomedical Chromatography
- Vol. 35 (4) , e5019
Stability‐indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of metformin, linagliptin, and empagliflozin in bulk and pharmaceutical dosage form
A rapid stability‐indicating reversed phase‐ultrapure liquid chromatography (RP‐UPLC) was developed and validated for the estimation of metformin (MET), linagliptin (LIN), and empagliflozin (EMP) combination in bulk and tablet dosage form using Kromasil C18 column (2.1 × 50 mm, 1.8 μm) as a stationary phase and a mixture solution of 40% phosphate buffer (pH = 3) and 60% acetonitrile as mobile phase at a flow rate of 0.6 mL/min. The detection was performed at 248 nm using a photodiode array detector. The linearity, sensitivity, selectivity, robustness, specificity, precision, and accuracy were determined. The peak area response–concentration curve was rectilinear over the range of 50–150 (MET), 5–15 (LIN), and 10–30 μg/mL (EMP) with quantitation limits of 0.042 (MET), 0.023 (LIN), and 0.059 μg/mL (EMP). The proposed method was successfully validated for the determination of MET, LIN, and EMP simultaneously in combined tablet dosage form. The performance of the proposed method was compared with reported RP‐UPLC methods and found to be rapid and economical. The developed and validated stability‐indicating RP‐UPLC method was appropriate for the quality control and drug analysis.